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Abstract
Objectives: Pancreatic fistula (PF) predicts mortality and morbidity in patients undergoing pancreati-
coduodenectomy (PD). This study aimed to assess whether isolated Roux loop pancreaticojejunostomy
(IPJ) is superior to conventional pancreaticojejunostomy (CPJ).hpb_051 326..331
Methods: Between September 2003 and July 2007, we performed 108 PDs. All patients underwent
classical Kausch–Whipple PD with pancreaticojejunostomy (PJ). Patients were divided into two groups
based on the type of PJ. Patients in group 1 underwent IPJ and those in group 2 underwent CPJ. A
retrospective analysis of prospectively maintained data was performed to compare outcomes in the two
groups.
Results: There were 53 patients in group 1 and 55 in group 2. The two groups were comparable in both
pre- and intraoperative parameters. The overall incidence of PF was 10.1% (five cases in group 1 vs. six
in group 2). The course of clinically significant PF was similar in both groups in terms of fistula behaviour,
management and the duration of spontaneous closure. Two patients in each group died. Overall com-
plications, mortality and length of hospital stay were also similar; however, duration of surgery was
significantly higher in group 1 vs. group 2 (442 min and 370 min, respectively; P = 0.005).
Conclusions: Isolated Roux loop pancreaticojejunostomy is not superior to conventional PJ; instead, it
increases the duration of surgery.
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Introduction
Pancreaticoduodenectomy (PD) has evolved over time to become
a safe and acceptable therapeutic option for patients with pancre-
atic and periampullary tumours.Although the operative mortality
of PD has reduced, morbidity remains high.1,2 Leakage from the
pancreaticoenteric anastomosis (PEA) remains the principal
factor for procedure-related morbidity. A variety of techniques
have been described to reduce the chances of formation of a
pancreatic fistula (PF).3 Despite the diverse range of methods
described for PEA, the incidence of PF has not changed signifi-
cantly over time (9.9%–28.5%).4,5 One of the proposed methods
of reconstruction after PD is to perform an isolated Roux loop
pancreaticojejunostomy (IPJ). Proponents of this technique
believe that the diversion of bile away from the pancreaticojejun-
ostomy (PJ) site minimizes the pancreatic enzyme activation and
this reduces the risk of PF formation.6 Another argument cited in
favour of using a Roux loop in PJ relies on the belief that, if a PF
fistula forms, it will be a ‘pure’ pancreatic fistula and these fistulae
cause lesser complications compared with complex PF, in which
the bile activates the pancreatic juice, with further repercussions.
Although some series have reported good results with IPJ, there
has been no comparative study to assess the superiority of this
method of reconstruction over conventional pancreaticojejunos-
tomy (CPJ) in which the same jejunal loop is used for the pan-
creatic, biliary and gastric anastomosis. We have used both
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methods of reconstruction and this paper reports our experience
with them.
Materials and methods
This report is a retrospective review of 108 consecutive PD pro-
cedures performed by a single surgical team in a tertiary care
centre between September 2003 and July 2007. Detailed informa-
tion on these patients was maintained on a prospective database.
Patient demographics and characteristics were carefully recorded.
Preoperative imaging included a combination of abdominal
ultrasound, contrast-enhanced computed tomography (CT) or
magnetic resonance imaging of the abdomen and endoscopic ret-
rograde cholangiopancreatography. Intraoperative features, such
as tumour size, pancreatic duct diameter, consistency of pancreas,
type of PJ anastomosis, use of pancreatic stent, duration of
surgery and blood loss, were carefully documented. We divided
the patients into two groups based on the type of PJ. In the initial
53 patients, operated between September 2003 and July 2005
(group 1), PJ was constructed with an isolated loop of jejunum
(IPJ). In the 55 patients operated between August 2005 and July
2007 (group 2), conventional PJ (CPJ) with a single loop repre-
sented the method of reconstruction. Apart from the type of
reconstruction, the operative procedure was similar in both
groups.
Operative details
All patients underwent classical Kausch–Whipple PD. Duct-to-
mucosa pancreaticojejunostomy was performed using 5/0 poply-
dioxanone monofilament interrupted sutures for the pancreatic
duct and jejunal mucosa and 3/0 interrupted silk sutures between
the capsule of pancreas and the seromuscular layer of jejunum.An
internal pancreatic stent was placed when the pancreatic duct
diameter was <3 mm. In group 1 (IPJ), a 40-cm isolated loop of
jejunum was passed through the mesocolon for PJ. The remaining
reconstruction was completed by end-to-side bilioenteric anasto-
mosis followed by gastrojejunostomy from the distal loop of
jejunum and the jejunojejunostomy was constructed after gas-
trojejunostomy (Fig. 1). In group 2 (CPJ), the reconstruction was
performed using a single, retrocolic jejunal loop. Pancreaticoje-
junostomy was performed first, followed by hepaticojejunostomy
and posterior gastrojejunostomy at a distance of 15–20 cm each
(Fig. 2). All patients in both groups received octreotide 150 mg i.v.
bolus at the time of constructing the PJ, followed by 150 mg
administered subcutaneously at 8-hourly intervals and continued
for the following 3 days until enteral feeding began. In patients
with clinical evidence of PF, octreotide was continued further
based on the clinical response. Octreotide was discontinued if the
fistula output did not reduce or any definitive intervention was
performed.
All postoperative complications were recorded. Pancreatic
fistula was defined as drainage of any measurable volume of fluid
with fluid amylase more than or equal to three times the upper
limit of normal serum value on postoperative day 3 or later.5 We
routinely measure drain fluid amylase on postoperative days 1, 3
and 7. The clinical behaviour of patients with PF was entered
prospectively into the database, with specific focus on the nature
of PF, and its presentation, management and outcome.
The International Study Group on Pancreatic Fistula (ISGPF)
definition for PF5 was used retrospectively in patients operated
before July 2005 on the basis of the essential information held in
our prospective database. All cases of postoperative PF were iden-
tified as representative of either pure or complex fistulae depend-
ing on the nature of the draining fluid. The presence of bile or
enteric contents suggested a complex fistula, whereas the presence
of clear, water-like fluid suggested a pure PF. In any suspicion of
intra-abdominal sepsis, CT scans were liberally performed.
Delayed gastric emptying (DGE) was defined as the need for
nasogastric intubation for >10 postoperative days, inability to
resume enteral feed at 14 days after surgery, need of prokinetics
for >10 days or re-insertion of the nasogastric tube.7 Length of
hospital stay was defined as the period from the first postoperative
Figure 1 Pancreaticoenteric reconstruction in group 1. PJ, pancre-
aticojejunostomy; HJ, hepaticojejunostomy; GJ, gastrojejunostomy;
JJ, jejunojejunostomy
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day until discharge from hospital. Death within the same hospital
admission or within 30 days of surgery was considered as opera-
tive mortality.
The primary endpoint of assessment concerned the presence or
absence of pancreas-specific complications, which included death
or leakage of pancreatoenteric or bilioenteric anastomosis. The
main focus was on the incidence, type, behaviour and manage-
ment of the PF in the two groups. Secondary endpoints included
duration of surgery and length of postoperative hospital stay.
Statistical methods
spss (Version 10.0; SPSS, Inc., Chicago, IL, USA) was used for
data analysis. To test significance, Student’s t-test was used for
continuous variables and chi-squared or Fischer’s exact test was
used for categorical variables. A P-value of <0.05 was considered
significant.
Results
The two groups were comparable in terms of baseline clinico-
pathological parameters (Table 1). Subjects included 81 men and
27 women,with a mean age of 54.3 years (standard deviation [SD]
 11.2 years, range 18–80 years). The indications for PD in order
of frequency were ampullary adenocarcinoma, carcinoma in the
head of pancreas, duodenal adenocarcinoma, lower-end common
bile duct (CBD) cholangiocarcinoma, carcinoid tumour, and
others, which included three patients in group 1 (chronic pancre-
atitis, n = 2; cystic tumour of the pancreas, n = 1) and five patients
in group 2 (chronic pancreatitis, n = 3; cystic tumour, n = 1;
chronic inflammation with lymphocytic infiltration, n = 1). Intra-
operative findings were comparable in the two groups for tumour
size, consistency of pancreas and pancreatic duct diameter
(Table 1).
The mean duration of surgery was 442 min (SD  32.0 min,
range 300–510 min) in group 1 vs. 370 min (SD  38.5 min,
range 240–500 min) in group 2 (P = 0.005, with 95 % confidence
interval [CI] 57.0–84.1) (Table 2). Intraoperative blood loss was
similar in the two groups. Mean recorded blood loss was 350 ml
(SD  78 ml, range 150–650 ml) and 330 ml (SD  89 ml, range
125–730 ml) in groups 1 and 2, respectively (P = 0.780). Two
patients in each group required a transfusion of 1 unit of packed
red cells and only one patient in each group needed 2 units.
Octreotide was discontinued once enteral feed was started, except
in patients with PF (five in group 1, six in group 2), who received
octreotide for longer. The mean duration of octreotide use in
patients with PF was 11 4.6 days in group 1 vs. 12.8 3.1 days
in group 2; this difference did not attain statistical significance
(P = 0.523).
A total of 32 of 108 (29.6%) patients developed some form of
postoperative complication. The complications ranged from PF to
DGE, intra-abdominal bleeding and wound infection. The inci-
dence and nature of postoperative complications were similar in
the two groups (Table 2).
We followed the clinical course of PF in both groups of patients.
Rates of incidence of PF were similar in both groups (five patients
in group 1 and six in group 2; P = 0.800, odds ratio [OR] 0.85, 95%
CI 0.24–2.97) and followed a similar clinical course (Fig. 3). There
were no differences in the incidence of pure or complex fistulae or
in the duration of their spontaneous closure (Fig. 3). Four
patients developed intra-abdominal bleeding postoperatively
(two in each group; P = 1.000). One patient in each group pre-
sented with blood in the abdominal drain. Angiography was sug-
gestive of bleed from the PJ site in both cases. These patients
underwent laparotomy (Fig. 3). Of the remaining two patients
with intra-abdominal bleed, one patient in group 1 bled from
hepaticojejunostomy and one patient in group 2 bled from gas-
trojejunostomy. Both these patients were managed conservatively.
Four (3.2%) patients died, two in each group (P = 1.000). In
group 1, death resulted from intra-abdominal bleeding from the
PJ site secondary to PF in one case and cardiac arrhythmia in the
other. In group 2, death was caused by intra-abdominal bleed
from the PJ site secondary to PF in one case and chest infection in
the other. The mean length of hospital stay was similar in the two
groups, at 10.1 days (SD  3.7 days, range 5–27 days) in group 1
Figure 2 Pancreaticoenteric reconstruction in group 2. PJ, pancre-
aticojejunostomy; HJ, hepaticojejunostomy; GJ, gastrojejunostomy
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Table 1 Clinicopathological parameters of patients (n = 108) undergoing pancreaticoduodenectomy
Preoperative parameters Group 1 (IPJ) (n = 53)
(range)  SD
Group 2 (CPJ) (n = 55)
(range)  SD
P-value
Age, years 53.3 (32–80)  12.1 53.5 (18–74)  10.1 0.931
Sex, male/female 40 (75.4%)/13 (24.6%) 41 (74.5%)/14 (25.6%) 0.955/0.980
Diagnosis
Ampullary carcinoma 24 (45.3%) 25 (45.5%) 0.978
HOP carcinoma 12 (22.6%) 13 (23.6%) 0.918
Duodenal carcinoma 3 (5.7%) 6 (10.9%) 0.345
Lower-end CBD carcinoma 10 (18.9%) 4 (7.3%) 0.082
Carcinoid tumour 1 (1.9%) 2 (3.6%) 0.583
Others 3 (5.7%) 5 (9.1%) 0.513
Endobiliary stent
Yes 14 (26.4%) 17 (30.9%) 0.662
No 39 (73.6%) 38 (69.1%) 0.782
Haemoglobin (g/dl) 11.0 (6.0–15.6)  2.0 11.7 (7.0–14.2)  1.7 0.602
WBC count, 103/mm3 11.1 (9.6–14.1)  3.6 10.9 (6.36–13.1)  3.1 0.782
Bilirubin, mg/dl 7.4 (0.3–24.1)  5.2 5.6 (0.4–29)  4.9 0.835
Intraoperative parameters
Tumour size, cm 2.96 (0.5–10)  1.8 2.66 (1–8)  1.5 0.371
MPD diameter, mm 5.41 (2–9)  2.5 5.11 (2–8)  2.3 0.546
Pancreatic consistency
Soft 35 (66.0%) 41 (74.6%) 0.598
Hard 18 (34.0%) 14 (25.4%) 0.419
PJ stent
Yes 14 (26.4%) 17 (30.9%) 0.515
No 39 (73.6) 38 (69.1%) 0.919
PJ anastomosis
Duct to mucosa 50 (94.3%) 49 (89.0%) 0.812
Dunking 03 (05.7%) 06 (11.0%) 0.098
IPJ, isolated Roux loop pancreaticojejunostomy; CPJ, conventional pancreaticojejunostomy; SD, mean standard deviation; HOP, head of pancreas;
CBD, common bile duct; WBC, white blood cell; MPD, main pancreatic duct; PJ, pancreaticojejunostomy
Table 2 Comparison of clinical outcomes between the two groups (n = 108)
Outcome Total (n = 108) Group 1 (IPJ) n = 53 Group 2 (CPJ) n = 55 P-value (group 1
vs. group 2)
Overall complications 32 (29.6%) 17 (32%) 15 (27.3%) 0.674
Nature of complications
Pancreatic fistula 11 (10.1%) 5 (9.4%) 6 (10.9%) 0.800
DGE 9 (8.3%) 5 (9.4%) 4 (7.2%) 0.739
Wound infection 8 (7.4%) 5 (9.4%) 3 (5.4%) 0.484
Bleeding 4 (3.7%) 2 (3.7%) 2 (3.6%) 1.000
Operative mortality 4 (3.7%) 2 (3.7%) 2 (3.6%) 1.000
Mean duration of surgery, min (95% CI, OR) 442 (300–510)  32.0 370 (240–500)  38.5 0.005
Mean hospital stay, days (95% CI, OR) 10.1 (5–27)  3.7 9.5 (4–26)  5.0 0.483
IPJ, isolated Roux loop pancreaticojejunostomy; CPJ conventional pancreaticojejunostomy; DGE, delayed gastric emptying; CI, confidence interval;
OR, odds ratio
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and 9.5 days (SD  5.0 days, range 4–26 days) in group 2 (P =
0.483) (Table 2).
Discussion
Until recently, the reported incidence of PF following PD varied
greatly because of the lack of an accepted definition of PF. Since
the publication of a definition by the ISGPF,5 there has been some
uniformity in this regard. Using the current definition of PF, the
incidence of PF has been found to range between 9.9% and
28.5%.4 Certainly, attempts to reduce the incidence and compli-
cations of PF after PD remain challenging.
Consistency of the pancreas, size of the pancreatic duct8 and the
experience of the operating team9 determine the formation of PF
after PD.Many high-volume centres have reported low incidences
of PF after PD, but this is more a reflection of the experience of the
surgical team than it is a testimony of a particular method’s supe-
riority over others. There have been few randomized trials10–12
comparing different methods of performing pancreaticoenteric
anastomosis and these have produced variable results. Thus, it
appears to be familiaritywith aparticular technique that gives good
results rather than the inherent superiority of a particular
method.
Ideally, a reconstructive technique should not only minimize
the risk of PF formation, but should also ensure that, should a PF
form, its complications are averted or minimized. An isolated
jejunal loop for PEA is theoretically expected to achieve these
desired endpoints. As shown in previous studies, using an isolated
jejunal loop for PEA can minimize the risk of PF, although its
effect in terms of reducing PF-related morbidity is not clear.13–19 In
view of these expected advantages, we started using an isolated
Roux loop of jejunum for performing pancreaticojejunostomy,
but over time we noticed that this did not reduce the incidence of
PF and these fistulae were not totally benign. Analysis of our data
showed that PF formed with equal frequency in both groups and
PF after IPJ were not always innocent. Complication rates, chances
of PF and duration of spontaneous closure of fistulae did not
differ between the treatment groups. The PF were of same grade in
the two groups and one patient in each group died (Fig. 3). As the
isolated Roux loop PJ offered no advantage and the process of
fashioning an isolated loop of jejunummade the entire procedure
longer and more complex, we reverted to the classical method of
reconstruction using a single loop.
Why does IPJ fail to live up to expectations? Healing of the PEA
is dependent on various factors and the diversion of bile may not
be one of them. Even the activation of leaking pancreatic juice is
not solely dependent on the presence of bile: intestinal juices
themselves can activate pancreatic secretions. In two of our
patients with IPJ, the PF was complex in nature; a possible expla-
nation for this may involve the disruption of biliary or gastric
anastomosis by pancreatic enzymes from the leaking PJ.
The only difference between the two groups concerned dura-
tion of surgery. Duration of surgery in group 1 was significantly
greater than in group 2. This is understandable because group 1
surgery required a 40-cm jejunal loop and an additional anasto-
mosis (i.e. jejunojejunostomy) to be constructed.
Pancreaticoduodenectomy (n = 108)
PF (n = 11)
Group I (n = 5)
Isolated Roux loop pancreaticojejunostomy
PPF-3, CPF-2
Group II (n = 6)
Conventional pancreaticojejunostomy
PPF-3, CPF-3
Presentation
Gr A-2, B-3, C-1
Presentation
Gr A-2, B-2, C-1
ManagementManagement
Outcome
DOC- 39 days (22–109 days)
Outcome
DOC- 33 days (14–114 days)
PCD-3 Laparotomy-1Conservative-2Laparotomy-1Conservative-2 PCD-2
IAB-1 IAB-1IAD-4 IAD-5
Discharged-5 Death-1Discharged-4 Death-1
Figure 3 Clinical course of pancreatic fistulae in groups 1 (isolated Roux loop pancreaticojejunostomy) and 2 (conventional pancreaticoje-
junostomy). PF, pancreatic fistula; PPF, pure pancreatic fistula; CPF, complex pancreatic fistula; Gr, grade; IAB, intra-abdominal bleed; IAD,
increased abdominal drainage; PCD, percutaneous drainage; DOC, duration of spontaneous closure
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Although this is not a randomized study, our observations
suggest that isolated Roux loop pancreaticojejunostomy does not
offer any advantage over conventional reconstruction in PD and
the difference in operative time is related to the construction of
isolated loop itself.
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